Raymond James Reiterates Sarepta Therapeutics (SRPT) at Market Perform, "Risk/Reward into Pivotal Phase 3 EMBARK Data Looks Compelling"
Tweet Send to a Friend
Raymond James analyst Danielle Brill reiterated a Market Perform rating on Sarepta Therapeutics (NASDAQ: SRPT) following the company's Q4 report ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
